Loading…
Lowering prostate cancer risk involves monitoring specific PSA metrics and considering certain medications, according to experts.
Our read is that lowering prostate cancer risk is well supported by expert consensus, focusing on advanced diagnostic interpretations and potential pharmaceutical interventions.
Experts suggest that a nuanced approach to prostate-specific antigen (PSA) metrics is crucial, moving beyond PSA alone to consider volume and velocity.
Additionally, certain medications may play a role in prostate health and risk reduction.
New research challenging the efficacy of tadalafil for prostate cancer risk reduction, or updated guidelines on PSA interpretation that contradict current expert advice, would alter our verdict.
The intervention improves the primary outcome at standard doses in healthy adults.
The effect size is large enough to matter clinically, not just statistically.
The effect size is large enough to matter clinically, not just statistically.
Mechanistic and trial evidence converge on a real, replicable effect.
The effect size is large enough to matter clinically, not just statistically.
Confounding and publication bias inflate the apparent benefit.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.
Confounding and publication bias inflate the apparent benefit.
The headline effect shrinks once you account for trial quality.